Dietary Therapy for Children with Hypercholesterolemia



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Accumulating evidence clearly shows that atherosclerosis begins in youth. The National Cholesterol Education Program (NCEP) has recommended that children at high risk of developing coronary artery disease as adults be screened so that those with elevated low-density lipoprotein (LDL) cholesterol levels can be treated, primarily by modification of diet. The initial approach to these youthful patients is to use the NCEP step I diet. This diet provides calories and nutrients that support normal growth and development, but limits saturated fat and total fat intake to no more than 10 and 30 percent of total calories, respectively, and cholesterol intake to no more than 100 mg per 1,000 kcal per day, to a maximum of 300 mg. If the goal of reducing the LDL cholesterol level to below 130 mg per dL (3.35 mmol per L) is not achieved, the more restrictive step II diet should be initiated. However, the step II diet may not provide sufficient calories and nutrients to support normal growth and development; therefore, trained nutritionists may be required to effectively manage a child on this diet.

Cardiovascular disease caused by atherosclerosis is the leading cause of death worldwide.1 Clinical evidence, epidemiologic data and postmortem studies provide convincing evidence that atherosclerosis begins in childhood. Children with homozygous familial hypercholesterolemia develop significant coronary heart disease (CHD) in the first decade of life and frequently die of myocardial infarction before 20 years of age.24 Serum cholesterol levels measured at 22 years of age are predictive of the risk for developing CHD over the next 30 to 40 years.5 Data from the Framingham Study6 show that cholesterol levels measured in young adults are predictive of CHD mortality 30 years later. In persons with familial hypercholesterolemia, there is a direct association between the duration and severity of hypercholesterolemia and extravascular lipid deposition in tissues.7

Scope and Epidemiology of the Cholesterol Problem

Epidemiologic data support the relationship between childhood and adult cholesterol levels,813 and a relationship between hyperlipidemia in the children and premature CHD in the parents.14,15 Pathologic findings have provided further evidence of the early development of atherosclerosis: young soldiers killed in the Korean War were found, with high frequency, to have advanced coronary artery lesions.16 Quantitative postmortem estimation17 of atherosclerosis in coronary arteries and aortas of children and young adults demonstrate a significant relationship between hyperlipidemia and the extent of atherosclerosis. In agreement with the accumulating evidence, it was recently demonstrated that cardiovascular risk factors in children are related to the severity of atherosclerosis found postmortem in such persons who died as young adults.18

Evidence of Need to Treat Hypercholesterolemia

Studies in adults provide evidence that reduction of serum cholesterol concentrations lowers the risk of developing CHD.19 The effectiveness of diet in reducing total and low-density lipoprotein (LDL) cholesterol levels is well established.20 Furthermore, studies in young children and adolescents have shown that when adequate calories and nutrients are provided, cholesterol-lowering diets do not impair growth or development.2125

Based on these findings, the National Cholesterol Education Program (NCEP) Expert Panel on Blood Cholesterol in Children and Adolescents recommended dietary intervention to lower LDL cholesterol levels in adolescents and children at least two years of age with a family history of cardiovascular disease or parental hypercholesterolemia.26 Because dietary treatment is safe and often effective, physicians should be alert for opportunities to provide appropriate consultation and treatment or to refer patients and families to other health care professionals for consultation.

Approach to Drug Therapy of Hypercholesterolemia

The approach to drug therapy for hypercholesterolemia in childhood can also be found in the NCEP guidelines26 and in recent reviews27,28 of the subject. The recommendation in the original NCEP guidelines is to augment dietary treatment with the use of bile acid sequestrants in children more than 10 years of age who, after six months to one year of dietary treatment, have failed to lower their LDL cholesterol level to less than 190 mg per dL (4.90 mmol per L), or to below 160 mg per dL (4.10 mmol per L) if they have a family history of premature cardiovascular disease or two or more other risk factors (e.g., low high-density lipoprotein [HDL] levels, diabetes, obesity, hypertension, cigarette smoking and physical inactivity). A number of systemically acting lipid-lowering drugs have proved to be successful in secondary29,30 and primary31 prevention of CHD in adults. Because this article's focus is on dietary therapy and because of the lack of data on the safety of prolonged use of these medications in children, we will not further discuss their use in this article.

Which Children Should Be Screened?

The NCEP has recommended a selective approach in screening children for hypercholesterolemia. Screening should be performed in children more than two years of age who have a positive family history of premature cardiovascular disease or parental hypercholesterolemia.

Positive family history of premature cardiovascular disease is defined as a parent, grandparent or first-degree aunt or uncle who experienced one of the following before the age of 55: myocardial infarction, angina pectoris, peripheral vascular disease, cerebrovascular disease, sudden cardiac death or documented coronary atherosclerosis.

Parental hypercholesterolemia is defined as a total blood cholesterol level of 240 mg per dL (6.20 mmol per L) or higher. Cholesterol levels should also be obtained in patients who smoke, have diabetes mellitus, are obese or have hypertension.

Initial Evaluation and Follow-up

Lipid and lipoprotein measurements should be made by an experienced laboratory, especially one that participates in the voluntary quality control program of the Centers for Disease Control and Prevention (CDC). Studies should be performed twice, and an average of the two values should be used to determine further evaluation and treatment.

In children with a positive family history of premature cardiovascular disease, a fasting lipoprotein analysis (total cholesterol, total triglycerides, HDL and LDL cholesterol levels) should be obtained. In children, fasting means consuming nothing except water after midnight. Table 1 provides acceptable, borderline and high LDL cholesterol levels in children.

TABLE 1.

Dietary Intervention Points in Children and Adolescents with Cardiovascular Risk Factors*

Category Total cholesterol (mg per dL) LDL cholesterol (mg per dL) Dietary intervention

Acceptable

< 170 (4.40 mmol per L)

< 110 (2.85 mmol per L)

Recommended population eating pattern

Borderline

170 to 199 (5.15 mmol per L)

110 to 129 (3.35 mmol per L)

AHA step I diet, other risk factor intervention

High

> 200 (5.20 mmol per L)

> 130 (3.40 mmol per L)

AHA step I diet; step II if necessary


LDL = low-density lipoprotein; AHA = American Heart Association.

*—Interventions based on cholesterol levels. Risk factors include a family history of premature cardiovascular disease or hypercholesterolemia.

Adapted with permission from National Cholesterol Education Program Coordinating Committee. Report of the Expert Panel on Blood Cholesterol in Children and Adolescents. Bethesda, Md.: National Heart, Lung, and Blood Institute, 1991. NIH publication no. 91–2732.

TABLE 1.   Dietary Intervention Points in Children and Adolescents with Cardiovascular Risk Factors*

View Table

TABLE 1.

Dietary Intervention Points in Children and Adolescents with Cardiovascular Risk Factors*

Category Total cholesterol (mg per dL) LDL cholesterol (mg per dL) Dietary intervention

Acceptable

< 170 (4.40 mmol per L)

< 110 (2.85 mmol per L)

Recommended population eating pattern

Borderline

170 to 199 (5.15 mmol per L)

110 to 129 (3.35 mmol per L)

AHA step I diet, other risk factor intervention

High

> 200 (5.20 mmol per L)

> 130 (3.40 mmol per L)

AHA step I diet; step II if necessary


LDL = low-density lipoprotein; AHA = American Heart Association.

*—Interventions based on cholesterol levels. Risk factors include a family history of premature cardiovascular disease or hypercholesterolemia.

Adapted with permission from National Cholesterol Education Program Coordinating Committee. Report of the Expert Panel on Blood Cholesterol in Children and Adolescents. Bethesda, Md.: National Heart, Lung, and Blood Institute, 1991. NIH publication no. 91–2732.

If there is no family history of premature cardiovascular disease, but the parents have hypercholesterolemia or other risk factors, a nonfasting total cholesterol level is a sufficient initial test. Acceptable levels are less than 170 mg per dL. If the total cholesterol is elevated above this level, a fasting protein analysis should be performed.

In a child with a high cholesterol level (total cholesterol or LDL cholesterol), screening tests for secondary causes of hypercholesterolemia (in particular, diabetes and diseases of the thyroid, liver and kidney) should be performed. Certain medications such as steroids, anticonvulsants and oral contraceptives can also be secondary causes. A more complete list of secondary factors can be found in the NCEP summary.26

Management

The goal of dietary treatment is to reduce LDL cholesterol levels. Table 1 provides the levels of total and LDL cholesterol at which dietary intervention is indicated in children and adolescents with a family history of hypercholesterolemia or premature cardiovascular disease. The recommended initial step to reduce cholesterol levels in children is the institution of a “heart-healthy” diet—one that is low in cholesterol and saturated fat and high in complex carbohydrates, and provides adequate energy for growth and the maintenance of a desirable weight.

AHA STEP I DIET

The American Heart Association (AHA) step I diet is equivalent to the NCEP step I diet and is well established for this purpose in adults and children more than two years of age.32 In a step I diet, no more than 30 percent of total calories come from fat, less than 10 percent of total calories come from saturated fat and dietary cholesterol is restricted to 100 mg per 1,000 kcal, not to exceed 300 mg per day. Many foods that are high in cholesterol are also high in saturated fat. A step I diet substitutes foods rich in monounsaturated and polyunsaturated fats for those rich in saturated fats. To provide effective dietary guidance, a complete dietary assessment is required. This is often difficult to accomplish in the typical office setting, but suggestions for estimating dietary intake and modifying the diet are noted below, as well as in Figure 1 and the accompanying patient information handout.

Food Diary

Figure 1.

A three-day food diary for the parent of a child being screened for hypercholesterolemia.

View Large

Food Diary


Figure 1.

A three-day food diary for the parent of a child being screened for hypercholesterolemia.

Food Diary


Figure 1.

A three-day food diary for the parent of a child being screened for hypercholesterolemia.

GOALS FOR DIETARY THERAPY

Although the ideal goal for dietary intervention is to lower the LDL cholesterol level to less than 110 mg per dL (2.85 mmol per L), in some cases this will not be possible. There are at least two reasons for this: (1) the child already consumes a heart-healthy diet or (2) the elevation may be high enough that the percentage of reduction achieved by dietary modification (typically no more than 20 percent and frequently less than 10 percent) still may not lower LDL cholesterol to the target goal. A more realistic goal for children and adolescents with a high level of LDL cholesterol is to reduce the level to lower than 130 mg per dL (3.35 mmol per L).

FOLLOW-UP AND INITIATION OF AHA STEP II DIET

To confirm the effectiveness of dietary changes, the LDL cholesterol level should be checked three to six months after treatment is started and yearly thereafter. Because lowering LDL cholesterol levels reduces the progression of CHD, any lowering of LDL cholesterol levels is valuable, even if the goal is not accomplished.

If the step I diet does not achieve the goal, the NCEP recommended dietary approach is for a trial of the more restrictive step II diet, which contains less than 7 percent of total calories from saturated fat and restricts dietary cholesterol to less than 75 mg per 1,000 kcal. Despite the seemingly modest reductions of the step II diet, there is the potential to develop nutritional deficiencies because of a more limited food selection. Therefore, patients placed on the step II diet should be closely monitored and should receive consultation with a clinician who has considerable nutritional expertise.

MONITORING FOR OTHER CARDIOVASCULAR RISK FACTORS

Other risk factors for cardiovascular disease, such as cigarette smoking, physical inactivity and obesity, are sometimes present in childhood and adolescence. Although they are not specifically addressed in this article, recommendations should be made for appropriate lifestyle modifications, such as maintaining a desirable weight, exercising, reducing sedentary activities (e.g., television watching) and smoking cessation. Involving all family members in the dietary changes and lifestyle modifications is important for long-term adherence to these treatment modalities.

Assessing Dietary Habits and Recommending Changes

Families need to learn to select foods that are low in total fat, particularly saturated fat, and cholesterol. The diet should include a variety of foods to ensure adequate intake of carbohydrates, protein and other essential nutrients, such as calcium and iron. Sufficient calories need to be consumed to ensure adequate growth and development.

In addition to lowering total fat and saturated fat intake, evidence has accumulated about the adverse effect of transunsaturated fatty acids (resulting from hydrogenation of oils, such as in margarines) on blood cholesterol levels.33 Hydrogenated fat consumption can be minimized by choosing liquid and soft fats over hardened fat products.

EVALUATION OF DIETARY HABITS

Ask the parents or child to keep a three-day food record before the next appointment (Figure 1). If they have not yet done this at the time of the follow-up visit, consider asking them to complete the food diary while they are in the waiting room, using a checklist of common foods. The items in the food diary can be arranged in two columns: foods listed on the left side are acceptable for eating on a daily basis; foods on the right side should be limited.

The physician can quickly scan the food diary and determine if the child is consuming too many inappropriate foods just by checking the right side of the page. Parent and child can be directed to use foods listed on the left side of the list as substitutes for those on the right side. They can also be referred to the AHA Cookbook for Kids. In addition, suggestions for lunchbox and snack ideas (see patient information handout) are helpful and should be provided. Families with Internet access should be encouraged to visit the AHA Web site (http://www.americanheart.org).

Table 2 provides the recommended daily caloric intake for girls and boys based on age and the 50th percentile of weight.34  Once the recommended total daily caloric intake is determined, as illustrated in Table 3, the maximal number of calories and grams that should come from fat and saturated fat can be calculated based on the NCEP recommendations for a step I diet (up to 30 percent of the daily caloric intake from all types of fat and up to 10 percent from saturated fat). Similar calculations can be made for the step II diet, using 7 percent of total daily calories as the upper limit for saturated fat. Total fat intake in children and adolescents should not be reduced to less than 20 percent of the daily caloric intake.32

TABLE 2.

Recommended Daily Caloric Intake in Children and Adolescents*

Age (years) Calories to maintain weight
Girls Boys

2

1,160

1,250

3

1,270

1,530

4

1,430

1,520

5

1,550

1,680

6

1,760

1,840

7

1,530

1,590

8

1,720

1,750

9

2,000

1,970

10

2,260

2,230

11

1,730

1,930

12

1,950

2,180

13

2,180

2,430

14

2,350

2,780

15

2,130

2,540

16

2,240

2,780

17

2,250

2,970

18

2,250

3,130


*—At the 50th weight percentile.

Reprinted with permission from National Research Council. Recommended dietary allowances. 10th ed. Washington, D.C.: National Academy of Sciences, 1989.

TABLE 2.   Recommended Daily Caloric Intake in Children and Adolescents*

View Table

TABLE 2.

Recommended Daily Caloric Intake in Children and Adolescents*

Age (years) Calories to maintain weight
Girls Boys

2

1,160

1,250

3

1,270

1,530

4

1,430

1,520

5

1,550

1,680

6

1,760

1,840

7

1,530

1,590

8

1,720

1,750

9

2,000

1,970

10

2,260

2,230

11

1,730

1,930

12

1,950

2,180

13

2,180

2,430

14

2,350

2,780

15

2,130

2,540

16

2,240

2,780

17

2,250

2,970

18

2,250

3,130


*—At the 50th weight percentile.

Reprinted with permission from National Research Council. Recommended dietary allowances. 10th ed. Washington, D.C.: National Academy of Sciences, 1989.

TABLE 3.

Sample Recommended Intake of Total and Saturated Fat Based on Daily Caloric Intake*

Total calories Calories from fat Grams from fat
Total fat (30% of calories) Saturated fat (10% of calories) Total fat (30% of calories) Saturated fat (10% of calories)

2,000

600 calories

200 calories

67 g

22 g


*—Based on recommendations for a nine-year-old girl at the 50th percentile for weight. Based on Table 2, her recommended caloric intake is 2,000 calories per day.

note: For a step I diet in this patient, the maximal number of calories from all types of fat (total fat) is derived by multiplying 2,000 by 30 percent and from saturated fat, by multiplying 2,000 by 10 percent. To convert the fat calories (total fat or saturated fat) to grams, use this conversion formula: 1 g of fat = 9 calories. Thus, 600 calories of total fat is equivalent to 600 divided by 9, or 67 g.

TABLE 3.   Sample Recommended Intake of Total and Saturated Fat Based on Daily Caloric Intake*

View Table

TABLE 3.

Sample Recommended Intake of Total and Saturated Fat Based on Daily Caloric Intake*

Total calories Calories from fat Grams from fat
Total fat (30% of calories) Saturated fat (10% of calories) Total fat (30% of calories) Saturated fat (10% of calories)

2,000

600 calories

200 calories

67 g

22 g


*—Based on recommendations for a nine-year-old girl at the 50th percentile for weight. Based on Table 2, her recommended caloric intake is 2,000 calories per day.

note: For a step I diet in this patient, the maximal number of calories from all types of fat (total fat) is derived by multiplying 2,000 by 30 percent and from saturated fat, by multiplying 2,000 by 10 percent. To convert the fat calories (total fat or saturated fat) to grams, use this conversion formula: 1 g of fat = 9 calories. Thus, 600 calories of total fat is equivalent to 600 divided by 9, or 67 g.

The Authors

RAANAN SHAMIR, M.D., is currently director of the Division of Pediatric Gastroenterology and Nutrition in the Department of Pediatrics at Rambam Medical Center, Haifa, Israel. He is also a lecturer in pediatrics at Tel Aviv University Sackler Faculty of Medicine. Dr. Shamir is a graduate of the Hebrew University Hadassah Medical School, Jerusalem, and obtained clinical and research training in pediatrics, nutrition and lipid metabolism at the Beilinson Medical Center, Israel, the Children's Hospital of Philadelphia and the Medical College of Pennsylvania, Philadelphia.

EDWARD A. FISHER, M.D., PH.D., is director of lipoprotein research at the Zena and Michael A. Wiener Cardiovascular Institute of the Mount Sinai School of Medicine of the City University of New York, N.Y. He is also a professor of medicine and pediatrics, and an attending physician at the Lipid Disorders Clinic at Mount Sinai Hospital. A graduate of the New York University School of Medicine, New York City, Dr. Fisher obtained clinical and research training at Duke University School of Medicine, Durham, N.C., Boston Children's Hospital, Massachusetts Institute of Technology, Boston, and the National Institutes of Health, Washington, D.C.

Address correspondence to Edward A. Fisher, M.D., Ph.D., Mount Sinai School of Medicine, 1 Gustave Levy Place, Box 1030, New York, NY 10029. Reprints are not available from the authors.

The authors thank committee member Stephen Daniels, M.D., Ph.D., and ad hoc writers Marilyn Cerino, R.D., and Betsy V. Harris, M.Ed., R.D., L.D., for their help in the preparation of the manuscript, and Jill F. Fisher, for editorial assistance.


Some of the material in this article and other relevant information can also be found on the American Heart Association Web site (http://www.americanheart.org).

REFERENCES

1. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 1997;349:1269–76.

2. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, et al., eds. The metabolic basis of inherited disease. New York: McGraw-Hill, 1995:1981–2030.

3. Sprecher DL, Schaefer EJ, Kent KM, Gregg RE, Zech LA, Hoeg JM, et al. Cardiovascular features of homozygous familial hypercholesterolemia: analysis of 16 patients. Am J Cardiol. 1984;54:20–30.

4. Brook GJ, Keidar S, Boulos M, Grenadier E, Wiener A, Shehada N, et al. Familial homozygous hypercholesterolemia: clinical and cardiovascular features in 18 patients. Clin Cardiol. 1989;12:333–8.

5. Klag MJ, Ford DE, Mead LA, He J, Whelton PK, Liang KY, et al. Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med. 1993;328:313–8.

6. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA. 1987;257:2176–80.

7. Schmidt HH, Hill S, Makariou EV, Feuerstein IM, Dugi KA, Hoeg JM. Relation of cholesterol-year score to severity of calcific atherosclerosis and tissue deposition in homozygous familial hypercholesterolemia. Am J Cardiol. 1996;77:575–80.

8. Clarke WR, Schrott HG, Leaverton PE, Connor WE, Lauer RM. Tracking of blood lipids and blood pressures in school age children: the Muscatine study. Circulation. 1978;58:626–34.

9. Orchard TJ, Donahue RP, Kuller LH, Hodge PN, Drash AL. Cholesterol screening in childhood: does it predict adult hypercholesterolemia? The Beaver County experience. J Pediatr. 1983;103:687–91.

10. Morrison JA, Namboodiri K, Green P, Martin J, Glueck CJ. Familial aggregation of lipids and lipoproteins and early identification of dyslipoproteinemia. The Collaborative Lipid Research Clinics Family Study. JAMA. 1983;250:1860–8.

11. Freedman DS, Shear CL, Srinivasan SR, Webber LS, Berenson GS. Tracking of serum lipids and lipoproteins in children over an 8-year period: the Bogalusa Heart Study. Prev Med. 1985;14:203–16.

12. Lauer RM, Lee J, Clarke WR. Factors affecting the relationship between childhood and adult cholesterol levels: the Muscatine Study. Pediatrics. 1988;82:309–18.

13. Lauer RM, Clarke WR. Use of cholesterol measurements in childhood for the prediction of adult hypercholesterolemia. The Muscatine Study. JAMA. 1990;264:3034–8.

14. Hennekens CH, Jesse MJ, Klein BE, Gourley JE, Blumenthal S. Cholesterol among children of men with myocardial infarction. Pediatrics. 1976;58:211–7.

15. Freedman DS, Srinivasan SR, Shear CL, Franklin FA, Webber LS, Berenson GS. The relation of apolipoproteins A-I and B in children to parental myocardial infarction. N Engl J Med. 1986;315:721–6.

16. Enos WF, Holmes RH, Beyer J. Coronary disease among United States soldiers killed in action in Korea: preliminary report. JAMA. 1953;152:1090–3.

17. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking. JAMA. 1990;264:3018–24.

18. Berenson GS, Srinivasan SR, Bao W, Newman WP 3d, Tracy RE, Wattigney MS. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med. 1998;338:1650–6.

19. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 1994;308:367–72.

20. Yu-Poth S, Zhao G, Etherton T, Naglak M, Jonnalagadda S, Kris-Etherton PM. Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis. Am J Clin Nutr. 1999;69:632–46.

21. The Writing Group for the DISC Collaborative Research Group. Efficacy and safety of lowering dietary intake of fat and cholesterol in children with elevated low-density lipoprotein cholesterol: The Dietary Intervention Study in Children (DISC). JAMA. 1995;273:1429–35.

22. Obarzanek E, Hunsberger SA, Van Horn L, Hartmuller VV, Barton BA, Stevens VJ, et al. Safety of a fat-reduced diet: the Dietary Intervention Study in Children (DISC). Pediatrics. 1997;100:51–9.

23. Niinikoski H, Lapinleimu H, Viikari J, Rönnemaa T, Jokinen E, Seppänen R, et al. Growth until 3 years of age in a prospective, randomized trial of a diet with reduced saturated fat and cholesterol. Pediatrics. 1997;99:687–94.

24. Shannon BM, Tershakovec AM, Martel JK, Achterberg CL, Cortner JA, Smiciklas-Wright HS, et al. Reduction of elevated LDL-cholesterol levels of 4-to 10-year-old children through home-based dietary education. Pediatrics. 1994;94:923–7.

25. Shea S, Basch CE, Stein AD, Contento IR, Irigoyen M, Zybert P. Is there a relationship between dietary fat and stature or growth in children three to five years of age? Pediatrics. 1993;92:579–86.

26. National Cholesterol Education Program Coordinating Committee. Report of the Expert Panel on Blood Cholesterol in Children and Adolescents. Bethesda, Md.: National Heart, Lung, and Blood Institute, 1991. NIH publication no. 91-2732.

27. Franklin FA Jr, Dashti N, Franklin CC. Evaluation and management of dyslipoproteinemia in children. Endocrinol Metab Clin North Am. 1998;27:641–54.

28. Lauer RM. An approach to cholesterol levels in children and adolescents. In Rifkin BM, ed. Lowering cholesterol in high-risk individuals and populations. New York: Dekker, 1995:133–48.

29. Scandinavian Simvastatin Survival Study group: randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study Lancet. 1994:1383–9.

30. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349–57.

31. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301–7.

32. Fisher EA, Van Horn L, McGill HC Jr. Nutrition and children. Circulation. 1997;95:2332–3.

33. Byers T. Hardened fats, hardened arteries? N Engl J Med. 1997;337:1544–5.

34. National Research Council. Recommended dietary allowances. 10th ed. Washington, D.C.: National Academy of Sciences, 1989.

This article is one in a series developed in collaboration with the American Heart Association. Guest editor of the series is Rodman D. Starke, M.D., Senior Vice President of Science and Medicine, American Heart Association, Dallas.


Copyright © 2000 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article